-
Sector Analysis
NewInternet from Sky – Can LEO Satellites Transform the Future of Connectivity? (Vol. 2)
As terrestrial broadband capabilities become increasingly saturated, low earth orbit (LEO) satellites emerge as a dynamic solution, capable of delivering high-speed, real-time data transmission with minimal latency. Positioned closer to Earth, these satellites offer a shorter and faster data transmission path, enhancing communication speeds and reliability. This advancement is particularly significant for data-intensive, industrial, and business-oriented applications, where real-time data exchange is crucial. Furthermore, the ubiquity of LEO satellite internet could transform connectivity, providing widespread internet access to diverse sectors...
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-576
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-576 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-819
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-819 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STAR-0602 in Vaginal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Vaginal Cancer Drug Details: STAR-0602 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Pancreatic Cancer Drug Details: CGX-1321 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Glofitamab in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glofitamab in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glofitamab in Non-Hodgkin Lymphoma Drug Details: Glofitamab (Columvi) is a bispecific monoclonal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-825 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-825 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-825 in Solid Tumor Drug Details: FT-825 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Chronic Myelomonocytic Leukemia (CMML) Drug Details: Nivolumab...